Evidence for the sequential formation of two complexes between an uptake inhibitor, GBR 12783 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine], and the neuronal transporter of dopamine

被引:9
作者
Do-Régo, JC
Hue, H
Costentin, J
Bonnet, JJ
机构
[1] UFR Med & Pharm, CNRS, UPRESA 6036, IFRMP 23, F-76803 St Etienne, France
[2] UFR Med & Pharm, Math Lab, F-76803 St Etienne, France
关键词
dopamine neuronal transporter; uptake inhibitor; GBR; 12783; kinetics; rat;
D O I
10.1046/j.1471-4159.1999.0720396.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Incubation of a crude synaptosomal fraction from rat striatum with GBR 12783 at 37 degrees C produced an inhibition of the specific uptake of [H-3]dopamine that increased with time. The inhibition increased when GBR 12783 was present during preincubation and incubation (IC50 = 1.85 +/- 0.1 nM) instead of incubation alone (IC50 = 25 +/- 3.5 nM). Time-course studies of uptake inhibition demonstrated that a first collision transporter-inhibitor complex (TI) was formed immediately after addition of GBR 12783 so that the initial uptake velocity (V-0) decreased for increasing concentrations of inhibitor (K-i greater than or equal to 20 nM). TI slowly isomerized to a more stable complex TI* (K-i* less than or equal to 5 nM) with a value of t(1/2) = 20-270 s. Fits of data to model 2 in which the steady-state uptake (V-S) is set to zero were generally preferred, suggesting that formation of TI* could tend to irreversibility, as a consequence of a very low reverse isomerization, As expected, k, V-0, and V-S tended to steady-state values in an asymptotic manner for high concentrations of GBR 12783, GBR 12783 at 2.5 nM produced a mixed inhibition of the uptake, with an increase in K-M and a decrease in V-max; these effects were improved for 10 nM GBR 12783 and at 20 degrees C. These results are discussed in relation to previous data concerning [H-3]GBR 12783 binding. The present work gives the first experimental demonstration that dopamine uptake blockers can act according to a two-step mechanism of inhibition; this is of great interest, because these inhibitors can oppose the effects of cocaine or amphetamine on the transporter according to a reaction that is partly nondependent on the concentration of the abused agent.
引用
收藏
页码:396 / 404
页数:9
相关论文
共 30 条
[2]   THERMODYNAMICS OF THE BINDING OF BTCP-(GK-13) AND RELATED DERIVATIVES ON THE DOPAMINE NEURONAL CARRIER [J].
BILLAUD, G ;
MENARD, JF ;
MARCELLIN, N ;
KAMENKA, JM ;
COSTENTIN, J ;
BONNET, JJ .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 268 (03) :357-363
[3]   SPECIFIC BINDING OF [H-3] GBR-12783 TO THE DOPAMINE NEURONAL CARRIER INCLUDED IN POLARIZED MEMBRANES [J].
BILLAUD, G ;
COSTENTIN, J ;
BONNET, JJ .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1993, 247 (03) :333-340
[4]   HIGH-AFFINITY BINDING OF [I-125] RTI-55 TO DOPAMINE AND SEROTONIN TRANSPORTERS IN RAT-BRAIN [J].
BOJA, JW ;
MITCHELL, WM ;
PATEL, A ;
KOPAJTIC, TA ;
CARROLL, FI ;
LEWIN, AH ;
ABRAHAM, P ;
KUHAR, MJ .
SYNAPSE, 1992, 12 (01) :27-36
[5]   HIGH-AFFINITY [H-3] GBR 12783 BINDING TO A SPECIFIC SITE ASSOCIATED WITH THE NEURONAL DOPAMINE UPTAKE COMPLEX IN THE CENTRAL-NERVOUS-SYSTEM [J].
BONNET, JJ ;
PROTAIS, P ;
CHAGRAOUI, A ;
COSTENTIN, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 126 (03) :211-222
[6]   GBR-12783, A POTENT AND SELECTIVE INHIBITOR OF DOPAMINE UPTAKE - BIOCHEMICAL-STUDIES INVIVO AND EXVIVO [J].
BONNET, JJ ;
COSTENTIN, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 121 (02) :199-209
[7]   SIMULTANEOUS EVALUATION BY A DOUBLE LABELING METHOD OF DRUG-INDUCED UPTAKE INHIBITION AND RELEASE OF DOPAMINE IN SYNAPTOSOMAL PREPARATION OF RAT STRIATUM [J].
BONNET, JJ ;
LEMASSON, MH ;
COSTENTIN, J .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (13) :2129-2135
[8]  
BONNET JJ, 1990, J PHARMACOL EXP THER, V253, P1206
[9]  
Carroll FI, 1997, NEUROTRANSMITTER TRA, P263
[10]   STUDIES ON DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF [H-3] DOPAMINE IN RAT-BRAIN TISSUE-SLICES [J].
HEIKKILA, RE ;
ORLANSKY, H ;
COHEN, G .
BIOCHEMICAL PHARMACOLOGY, 1975, 24 (08) :847-852